It's a question I have been wondering about for a few weeks. I watched the prices of others in the COVID game that are ahead of us. They're obviously all giants and they added billions in market value, but Moderna, for example, already had a lot of speculation built in and is up about 40% in the past month. That's a better comparison that the giant that Pfizer is. We all know CYDY was in the low $1.00 range pre-COVID, and while there are a lot more eyes on us today, we still don't have anything approved, and we aren't even talking about timeframes for getting a BLA to the FDA lately.
With EUA on the S/C population, we aren't going to blast off to $15-20 or anything, especially with more vaccines looking likely (Astra Zeneca to the game today), and some other MAB's in the m/m stage. The good thing is that even with a smaller piece of the pie, we would undoubtedly be in better financial shape to push other things forward without having to sell stock or borrow on toxic terms.